The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study.
Darbepoetin alfa
Epoetin alfa
Low-risk-intermediate-1-risk
Myelodysplastic syndrome
Treatment response
Journal
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
ISSN: 0971-4502
Titre abrégé: Indian J Hematol Blood Transfus
Pays: India
ID NLM: 9425818
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
30
04
2021
accepted:
10
06
2021
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
ppublish
Résumé
This study aimed to evaluate the clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndromes (MDS) in the real-life setting. A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin alfa or darbepoetin alfa were included. Hemoglobin levels and transfusion need were recorded before and during 12-month treatment. Hemoglobin levels were significantly higher at each follow up visit when compared to baseline levels in both epoetin alfa (mean ± SD 8.68 ± 1.0 g/dL at baseline vs. 9.83 ± 1.45, 9.99 ± 1.55, 10.24 ± 1.77 and 10.2 ± 1.5 g/dL, respectively) and darbepoetin alfa (8.83 ± 1.09 g/dL at baseline vs. 9.62 ± 1.37, 9.78 ± 1.49, 9.9 ± 1.39 and 10.1 ± 1.5 g/dL, respectively) groups ( The online version contains supplementary material available at 10.1007/s12288-021-01458-1.
Identifiants
pubmed: 35496974
doi: 10.1007/s12288-021-01458-1
pii: 1458
pmc: PMC9001769
doi:
Types de publication
Journal Article
Langues
eng
Pagination
299-308Informations de copyright
© Indian Society of Hematology and Blood Transfusion 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
Acta Haematol. 2008;120(2):104-7
pubmed: 18974634
Expert Opin Biol Ther. 2010 Apr;10(4):605-14
pubmed: 20201708
Curr Med Res Opin. 2011 May;27(5):951-60
pubmed: 21381892
Clinics (Sao Paulo). 2019;74:e771
pubmed: 31508719
Leukemia. 2018 Dec;32(12):2648-2658
pubmed: 29895954
Ann Oncol. 2014 Sep;25 Suppl 3:iii57-69
pubmed: 25185242
Blood. 2006 Sep 1;108(5):1497-503
pubmed: 16675707
Br J Haematol. 2019 Jan;184(2):134-160
pubmed: 30549002
Oncologist. 2011;16 Suppl 3:35-42
pubmed: 21930833
Blood. 2009 Sep 17;114(12):2393-400
pubmed: 19564636
J Support Oncol. 2005 Nov-Dec;3(6):419-26
pubmed: 16350429
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
Br J Haematol. 2008 Jul;142(3):379-93
pubmed: 18540943
Br J Haematol. 2016 Sep;174(5):730-47
pubmed: 27214305
Blood. 2013 Oct 24;122(17):2943-64
pubmed: 23980065
Semin Hematol. 2015 Oct;52(4):348-56
pubmed: 26404446
Acta Med Port. 2015 Nov-Dec;28(6):720-5
pubmed: 26849756
Pharmacotherapy. 2007 Mar;27(3):434-46
pubmed: 17316154
Leuk Res. 2015 Jun;39(6):586-91
pubmed: 25869077
Ann Hematol. 2008 Jul;87(7):527-36
pubmed: 18351340
Blood. 2008 Jan 15;111(2):574-82
pubmed: 17940203
Leukemia. 2017 Sep;31(9):1944-1950
pubmed: 28626220
Leuk Res. 2010 Nov;34(11):1430-6
pubmed: 20580086
Leuk Res. 2019 Jun;81:35-42
pubmed: 31005849
Ann Hematol. 2013 May;92(5):621-31
pubmed: 23358617
Am J Hematol. 2009 Jan;84(1):15-20
pubmed: 19006226
Leuk Lymphoma. 2010 Jun;51(6):1007-14
pubmed: 20367566
Ann Hematol. 2017 Dec;96(12):2025-2029
pubmed: 28975386
Br J Haematol. 2014 Feb;164(4):503-25
pubmed: 24372298
J Natl Compr Canc Netw. 2013 Jul;11(7):838-74
pubmed: 23847220
Br J Haematol. 2002 Jul;118(1):174-80
pubmed: 12100145
Br J Haematol. 2003 Mar;120(6):1037-46
pubmed: 12648074
Leuk Res. 2013 Jun;37(6):675-80
pubmed: 23523473